4012 Target Tip |
Product Characteristics | |||
|---|---|---|---|---|
| US Market Release | Jul-83 | Serial Number Prefix | HQ | |
| Registered US Implants | 93,700 | Type and/or Fixation | Transvenous, Vent., Tines | |
| Estimated Active US Implants | 6,500 | Polarity | Bipolar | |
| Steroid | No | |||
| Advisories | 1 | See 1991 Lead Survival Below Expectations | ||
| Ventricular Placement | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| System Longevity Study Results |
|
|||||||||
| Number of Leads Enrolled in Study | 2,543 | |||||||||
| Cumulative Months of Follow-Up | 151,162 | |||||||||
| Number of Leads Active in Study | 10 | |||||||||
| Qualifying Complications | 316 Total | |||||||||
| Conductor Fracture | 6 | |||||||||
| Extra Cardiac Stimulation | 3 | |||||||||
| Failure to Capture | 126 | |||||||||
| Failure to Sense | 77 | |||||||||
| Impedance Out of Range | 26 | |||||||||
| Insulation (ESC) | 9 | |||||||||
| Insulation (MIO) | 4 | |||||||||
| Insulation (not further defined) | 16 | |||||||||
| Medical Judgment | 1 | |||||||||
| Oversensing | 48 | |||||||||
